Private company
Biovest
Minneapolis-based biotechnology company
Biovest International, Inc (OTCQB: BVTI) was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma. Biovest filed to reorganize under chapter 11 bankruptcy in 2008 and 2013, BiovaxID was refused European marketing authorization in 2015, and Biovest's stock listing was revoked in 2017.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
- Industrypharmaceutical industry1
- HeadquartersMinneapolis1
- Websitewww.biovest.com
See how the biggest companies compare on our leaderboards
Biovest International, Inc (OTCQB: BVTI) was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma. Biovest filed to reorganize under chapter 11 bankruptcy in 2008 and 2013, BiovaxID was refused European marketing authorization in 2015, and Biovest's stock listing was revoked in 2017.2
Controversies and legal
Regulatory status
In December 2013, Biovest reported that the European Medicines Agency (EMA) accepted the Company's Marketing Authorization Application (MAA) for BiovaxID (submitted to EMA as “Dasiprotimut-T Biovest”), a personalized cancer vaccine for the treatment of non-Hodgkin's follicular lymphoma. The MAA validation confirms the submission is complete and begins the formal EMA review process intended to secure approval to market BiovaxID in the European Union and to allow prescription and sale of BiovaxID for the treatment of non-Hodgkin's follicular lymphoma in patients who have achieved a first complete remission.
Biovest submitted its MAA following the successful completion and long-term follow-up of two Phase 2 clinical trials and of one multi-center, randomized, Phase 3 clinical trial (all conducted in partnership with the U.S. National Cancer Institute) in which BiovaxID demonstrated it could induce powerful anti-tumor immune responses, eradicate residual tumor cells from patients’ blood following chemotherapy, and improve the duration of complete remissions by a median of 15.4 months relative to control.
From Wikipedia’s article on Biovest, shared under CC BY-SA 4.0.3
Links
- Websitewww.biovest.com1
- WikipediaBiovest
- WikidataQ4915390
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataBiovest on Wikidata
- 2WikipediaBiovest on Wikipedia
- 3WikipediaBiovest on Wikipedia (revision used)